弓形虫病治疗:从传统药物到纳米药物

doi:10.11843/j.issn.0366-6964.2023.05.007

摘要/Abstract

摘要： 刚地弓形虫(Toxoplasma gondii)是一种呈世界性分布的机会致病原虫,几乎感染所有的温血动物,引起人兽共患弓形虫病。免疫力正常的个体感染常呈隐性感染,无明显的临床症状;但免疫功能缺陷的人或动物感染则会导致严重后果,需进行有效治疗。目前,弓形虫病已是全世界绵羊和山羊流产的常见原因,该病给人类健康和畜牧业生产都造成了严重影响。因此,控制人和动物弓形虫病对公共卫生和畜牧业经济发展极为重要。以往用于弓形虫病治疗的药物,由于其副作用和/或疾病分期的特点,治疗效果大大受限,然而纳米药物可有效克服传统药物的局限性。本文就纳米技术在弓形虫病治疗方面的新进展作一综述,以期为抗弓形虫病药物的研究提供新思路。

关键词: 弓形虫, 传统药物, 纳米载药系统, 固体脂质纳米粒, 聚合物纳米粒子

Abstract: Toxoplasma gondii is a worldwide obligate intracellular protozoa that infects almost all warm-blooded animals and causes zoonotic toxoplasmosis. Individuals with normal immune function are often infected with Toxoplasma gondii without obvious clinical symptoms and show recessive infection, but pregnant women and individuals with immune deficiency can lead to serious consequences and need effective treatment. Toxoplasmosis is a common cause of abortion in sheep and goats worldwide. And it has a serious impact on human health and livestock production. Therefore, the control of human and animal toxoplasmosis is very important for public health and the economic development of animal husbandry. Previous drugs used to treat toxoplasmosis have been limited in their effectiveness due to side effects and/or disease staging. How-ever, nanoparticles can effectively overcome the limitations of traditional drugs. This article reviews the new progress of nanotechnology in the treatment of toxoplasmosis, in order to provide new ideas for the research of anti-toxoplasmosis drugs.

Key words: Toxoplasma gondii, traditional drugs, nano drug delivery system, solid lipidnanoparticles, polymer nanoparticles

中图分类号:

S853.32

孙晓敬, 张磊, 田甜, 马茜, 姚佳, 汪洋. 弓形虫病治疗:从传统药物到纳米药物[J]. 畜牧兽医学报, 2023, 54(5): 1834-1844.

SUN Xiaojing, ZHANG Lei, TIAN Tian, MA Xi, YAO Jia, WANG Yang. Unravelling Toxoplasma Treatment: Conventional Drugs toward Nanomedicine[J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(5): 1834-1844.

参考文献 76

[1]	MONTOYA J G, LIESENFELD O. Toxoplasmosis[J]. Lancet, 2004, 363(9425):1965-1976.
[2]	SAADATNIA G, GOLKAR M. A review on human toxoplasmosis[J]. Scand J Infect Dis, 2012, 44(11):805-814.
[3]	沈继龙, 余莉. 我国弓形虫病流行概况及防治基础研究进展[J]. 中国血吸虫病防治杂志, 2019, 31(1):71-76.SHEN J L, YU L. Prevalence and fundamental researches of prevention and treatment of toxoplasmosis in China:an overview[J]. Chinese Journal of Schistosomiasis Control, 2019, 31(1):71-76. (in Chinese)
[4]	WANG S, ZHOU Y H, NIU J Y, et al. Seroprevalence of Toxoplasma gondii infection in domestic cats in central China[J]. Parasite, 2017, 24:10.
[5]	侯永恒, 吕芳丽. 弓形虫感染与宿主细胞自噬的相互作用[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(4):537-541, 547.HOU Y H, LV F L. The interplay between Toxoplasma gondii infection and autophagy in host cells[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2021, 39(4):537-541, 547. (in Chinese)
[6]	DECEMBRINO N, COMELLI A, GENCO F, et al. Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation:do not forget it still exists[J]. Bone Marrow Transplant, 2017, 52(9):1326-1329.
[7]	HAMPTON M M. Congenital toxoplasmosis:a review[J]. Neonatal Netw, 2015, 34(5):274-278.
[8]	POSTOLACHE T T, COOK T B. Is latent infection with Toxoplasma gondii a risk factor for suicidal behavior?[J]. Exp Rev Anti Infect Ther, 2013, 11(4):339-342.
[9]	ZHANG Y H, CHEN H, CHEN Y, et al. Activated microglia contribute to neuronal apoptosis in Toxoplasmic encephalitis[J]. Parasit Vectors, 2014, 7:372.
[10]	姚娜, 龚静芝, 范益敏, 等. 弓形虫病治疗药物的研究进展[J]. 中国畜牧兽医, 2020, 47(4):1250-1257.YAO N, GONG J Z, FAN Y M, et al. Research progress on drugs for the treatment of toxoplasmosis[J]. China Animal Husbandry & Veterinary Medicine, 2020, 47(4):1250-1257. (in Chinese)
[11]	BAGGISH A L, HILL D R. Antiparasitic agent atovaquone[J]. Antimicrob Agents Chemother, 2002, 46(5):1163-1173.
[12]	PAQUET C, YUDIN M H, Society of Obstetricians and Gynaecologists of Canada. Toxoplasmosis in pregnancy:prevention, screening, and treatment[J]. J Obstet Gynaecol Can, 2013, 35(1):78-79.
[13]	OMAR M, ABAZA B E, MOUSA E, et al. Effect of spiramycin versus aminoguanidine and their combined use in experimental toxoplasmosis[J]. J Parasit Dis, 2021, 45(4):1014-1025.
[14]	DUNAY I R, GAJUREL K, DHAKAL R, et al. Treatment of toxoplasmosis:historical perspective, animal models, and current clinical practice[J]. Clin Microbiol Rev, 2018, 31(4):e00057-17.
[15]	JORGE R, COELHO I N, SILVA-CUNHA A, et al. Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis[J]. Am J Ophthalmol Case Rep, 2021, 22:101093.
[16]	CHANG H R. The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis[J]. Int J STD AIDS, 1996, 7 Suppl 1:18-22.
[17]	SCHLOSSBERG D. Azithromycin and clarithromycin[J]. Med Clin North Am, 1995, 79(4):803-815.
[18]	SAITO H, MURATA Y, NONAKA M, et al. Screening of a library of traditional Chinese medicines to identify compounds and extracts which inhibit Toxoplasma gondii growth[J]. J Vet Med Sci, 2020, 82(2):184-187.
[19]	石琦,郝炳华,周玉玲,等.小鼠淋巴细胞体外抗弓形虫作用的实验研究[J].细胞与分子免疫学杂志,2003,19(5):493-495.SHI Q, HAO B H, ZHOU Y L, et al. Experimental study on the in vitro resistance to Toxoplasma gondii by murine lymphocyte[J]. Chinese Journal of Cellular and Molecular Immunology, 2003, 19(5):493-495. (in Chinese)
[20]	D'ANGELO J G, BORDÓN C, POSNER G H, et al. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle[J]. J Antimicrob Chemother, 2009, 63(1):146-150.
[21]	CHEN Q W, DONG K, QIN H X, et al. Direct and indirect inhibition effects of resveratrol against Toxoplasma gondii tachyzoites in vitro[J]. Antimicrob Agents Chemother, 2019, 63(3):e01233-18.
[22]	杨小迪,孙希萌,王旗,等. 金丝桃素体外抗刚地弓形虫速殖子效果的观察[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(3):203-207.YANG X D, SUN X M, WANG Q, et al. In vitro effect of hypericin against Toxoplasma gondii tachyzoites[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2016, 34(3):203-207. (in Chinese)
[23]	赵雅文, 郑萌, 李涛, 等. 白藜芦醇对弓形虫感染小鼠的治疗效果及毒副作用研究[J]. 热带医学杂志, 2020, 20(3):350-353.ZHAO Y W, ZHENG M, LI T, et al. Study on the therapeutic effect and side effects of resveratrol on acute Toxoplasma gondii infected mice[J]. Journal of Tropical Medicine, 2020, 20(3):350-353. (in Chinese)
[24]	SASAI M, PRADIPTA A, YAMAMOTO M. Host immune responses to Toxoplasma gondii[J]. Int Immunol, 2018, 30(3):113-119.
[25]	SHARIF M, SARVI S, PAGHEH A S, et al. The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades:a systematic review[J]. Can J Physiol Pharmacol, 2016, 94(12):1237-1248.
[26]	ABDULLAHI S A, UNYAH N Z, NORDIN N, et al. Phytochemicals and potential therapeutic targets on Toxoplasma gondii parasite[J]. Mini Rev Med Chem, 2020, 20(9):739-753.
[27]	于朝云, 张保德, 宁俊雅, 等. 中草药抗弓形虫作用机制的研究进展[J]. 中国血吸虫病防治杂志, 2015, 27(5):555-557, 559.YU C Y, ZHANG B D, NING J Y, et al. Advances in researches on mechanism of anti-Toxoplasma Chinese herbal medicine[J]. Chinese Journal of Schistosomiasis Control, 2015, 27(5):555-557, 559. (in Chinese)
[28]	GOO Y K, YAMAGISHI J, UENO A, et al. Characterization of Toxoplasma gondii glyoxalase 1 and evaluation of inhibitory effects of curcumin on the enzyme and parasite cultures[J]. Parasit Vectors, 2015, 8:654.
[29]	黄珮珺, 李芸茜, 戎国栋, 等. 黄芪对急性弓形虫感染小鼠的血清IFN-γ及IL-18的影响[J]. 临床检验杂志, 2005, 23(5):347-349.HUANG P J, LI Y X, RONG G D, et al. Impact of Astragalus membranaceus on levels of IFN-γ and IL-18 in sera from mice infected with Toxoplasma gondii[J]. Chinese Journal of Clinical Laboratory Science, 2005, 23(5):347-349. (in Chinese)
[30]	邱燕华, 翟斌涛, 尚小飞, 等. 桧烯抗弓形虫活性的体外评价[J]. 畜牧兽医学报, 2021, 52(10):2915-2923.QIU Y H, ZHAI B T, SHANG X F, et al. Evaluation of the activity of sabinene against Toxoplasma gondii in vitro[J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(10):2915-2923. (in Chinese)
[31]	程小艳, 朴莲荀. 中药抗弓形虫的作用及其机制的研究进展[J]. 华西药学杂志, 2016, 31(2):215-217.CHENG X Y, PU L X. Research progress on the effect and mechanism of traditional Chinese medicine against Toxoplasma gondii[J]. West China Journal of Pharmaceutical Sciences, 2016, 31(2):215-217. (in Chinese)
[32]	常江艳, 李朝, 非绍江, 等. 纳米技术在寄生虫学中的应用[J]. 中国畜牧兽医, 2017, 44(11):3294-3299.CHANG J Y, LI Z, FEI S J, et al. Application of nanotechnology in parasitology[J]. China Animal Husbandry & Veterinary Medicine, 2017, 44(11):3294-3299. (in Chinese)
[33]	戴建荣, 朱荫昌. 纳米药物研究进展[J]. 中国血吸虫病防治杂志, 2006, 18(1):74-77.DAI J R, ZHU Y C. Progress of research on nanodrugs[J]. Chinese Journal of Schistosomiasis Control, 2006, 18(1):74-77. (in Chinese)
[34]	DAR M J, MCELROY C A, KHAN M I, et al. Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis[J]. Expert Opin Drug Deliv, 2020, 17(1):97-110.
[35]	孔秋晨, 佘慧明, 杨粤军. 纳米抗菌材料的研究进展[J]. 生物化工, 2022, 8(1):158-163.KONG Q C, SHE H M, YANG Y J. Research progress of nanometer antibacterial materials[J]. Biological Chemical Engineering, 2022, 8(1):158-163. (in Chinese)
[36]	RAHMAN K, KHAN S U, FAHAD S, et al. Nano-biotechnology:a new approach to treat and prevent malaria[J]. Int J Nanomedicine, 2019, 14:1401-1410.
[37]	MACHADO L F, SANFELICE R A, BOSQUI L R, et al. Biogenic silver nanoparticles reduce adherence, infection, and proliferation of Toxoplasma gondii RH strain in HeLa cells without inflammatory mediators induction[J]. Exp Parasitol, 2020, 211:107853.
[38]	ADEYEMI O S, MURATA Y, SUGI T, et al. Nanoparticles show potential to retard bradyzoites in vitro formation of Toxoplasma gondii[J]. Folia Parasitol (Praha), 2019, 66:2019. 001.
[39]	AL EDHARI B, MASHREGHI M, MAKHDOUMI A, et al. Antibacterial and antibiofilm efficacy of Ag NPs, Ni NPs and Al2O3 NPs singly and in combination against multidrug-resistant Klebsiella pneumoniae isolates[J]. J Trace Elem Med Biol, 2021, 68:126840.
[40]	阮林高, 殷瑜. 金属纳米粒子与抗生素联用抗耐药菌[J]. 中国抗生素杂志, 2018, 43(8):971-978.RUAN L G, YIN Y. Combating drug-resistant bacteria by combining metal nanoparticles with antibiotics[J]. Chinese Journal of Antibiotics, 2018, 43(8):971-978. (in Chinese)
[41]	QUAN J H, GAO F F, ISMAIL H A H A, et al. Silver nanoparticle-induced apoptosis in ARPE-19 cells is inhibited by Toxoplasma gondii pre-infection through suppression of NOX4-dependent ROS generation[J]. Int J Nanomedicine, 2020, 15:3695-3716.
[42]	SHOJAEE S, FIROUZEH N, KESHAVARZ H, et al. Nanosilver colloid inhibits Toxoplasma gondii tachyzoites and bradyzoites in vitro[J]. Iran J Parasitol, 2019, 14(3):362-367.
[43]	NAFARI A, CHERAGHIPOUR K, SEPAHVAND M, et al. Nanoparticles:New agents toward treatment of leishmaniasis[J]. Parasite Epidemiol Control, 2020, 10:e00156.
[44]	ALAJMI R A, AL-MEGRIN W A, METWALLY D, et al. Anti- Toxoplasma activity of silver nanoparticles green synthesized with Phoenix dactylifera and Ziziphus spina-christi extracts which inhibits inflammation through liver regulation of cytokines in Balb/c mice[J]. Biosci Rep, 2019, 39(5):BSR20190379.
[45]	SIDDIQI K S, HUSEN A, RAO R A K. A review on biosynthesis of silver nanoparticles and their biocidal properties[J]. J Nanobiotechnol, 2018, 16(1):14.
[46]	EFTHIMIOU I, KALAMARAS G, PAPAVASILEIOU K, et al. ZnO, Ag and ZnO-Ag nanoparticles exhibit differential modes of toxic and oxidative action in hemocytes of mussel Mytilus galloprovincialis[J]. Sci Total Environ, 2021, 767:144699.
[47]	PISSUWAN D, VALENZUELA S M, MILLER C M, et al. A golden bullet? Selective targeting of Toxoplasma gondii tachyzoites using antibody-functionalized gold nanorods[J]. Nano Lett, 2007, 7(12):3808-3812.
[48]	PISSUWAN D, VALENZUELA S M, MILLER C M, et al. Destruction and control of Toxoplasma gondii tachyzoites using gold nanosphere/antibody conjugates[J]. Small, 2009, 5(9):1030-1034.
[49]	JAIN P K, LEE K S, EL-SAYED I H, et al. Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition:applications in biological imaging and biomedicine[J]. J Phys Chem B, 2006, 110(14):7238-7248.
[50]	KEYHANI A, ZIAALI N, SHAKIBAIE M, et al. Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model[J]. J Med Microbiol, 2020, 69(1):104-110.
[51]	FAN X Z, YAHIA L, SACHER E. Antimicrobial properties of the Ag, Cu nanoparticle system[J]. Biology (Basel), 2021, 10(2):137.
[52]	GUTIÉRREZ V, SEABRA A B, REGUERA R M, et al. New approaches from nanomedicine for treating leishmaniasis[J]. Chem Soc Rev, 2016, 45(1):152-168.
[53]	KHALIL N M, DE MATTOS A C, CARRARO T C M M, et al. Nanotechnological strategies for the treatment of neglected diseases[J]. Curr Pharm Des, 2013, 19(41):7316-7329.
[54]	ZAMANI P, MOMTAZI-BOROJENI A A, NIK M E, et al. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy[J]. J Cell Physiol, 2018, 233(7):5189-5199.
[55]	MELLORS J W, DEBS R J, RYAN J L. Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity[J]. Infect Immun, 1989, 57(1):132-137.
[56]	TACHIBANA H, YOSHIHARA E, KANEDA Y, et al. Protection of Toxoplasma gondii -infected mice by stearylamine-bearing liposomes[J]. J Parasitol, 1990, 76(3):352-355.
[57]	FRANCOLINI I, PIOZZI A, DONELLI G. Usnic acid:potential role in management of wound infections[M]//DONELLI G. Advances in Microbiology, Infectious Diseases and Public Health. Cham:Springer, 2018:31-41.
[58]	SI K W, WEI L L, YU X Z, et al. Effects of (+)-usnic acid and (+)-usnic acid-liposome on Toxoplasma gondii[J]. Exp Parasitol, 2016, 166:68-74.
[59]	王敏, 杨中澜, 周莉莉, 等. 固体脂质纳米粒吸入粉雾剂的研究进展[J]. 中国新药杂志, 2022, 31(6):567-572.WANG M, YANG Z L, ZHOU L L, et al. Research progress in inhaled powder aerosols of solid lipid nanoparticles[J]. Chinese Journal of New Drugs, 2022, 31(6):567-572. (in Chinese)
[60]	KHOSRAVI M, RAHIMI H M, DOROUD D, et al. In vitro evaluation of mannosylated paromomycin-loaded solid lipid nanoparticles on acute toxoplasmosis[J]. Front Cell Infect Microbiol, 2020, 10:33.
[61]	AZAMI S J, AMANI A, KESHAVARZ H, et al. Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis[J]. Eur J Pharm Sci, 2018, 117:138-146.
[62]	ANTON N, BENOIT J P, SAULNIER P. Design and production of nanoparticles formulated from Nano-emulsion templates-a review[J]. J Control Release, 2008, 128(3):185-199.
[63]	SCHÖLER N, KRAUSE K, KAYSER O, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis[J]. Antimicrob Agents Chemother, 2001, 45(6):1771-1779.
[64]	SHUBAR H M, LACHENMAIER S, HEIMESAAT M M, et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers[J]. J Drug Target, 2011, 19(2):114-124.
[65]	潘超, 王晓峰. 壳聚糖纳米粒子在药物递送系统中的应用进展[J]. 实用临床医药杂志, 2021, 25(4):116-120.PAN C, WANG X F. Research progress on application of chitosan nanoparticles in drug delivery system[J]. Journal of Clinical Medicine in Practice, 2021, 25(4):116-120. (in Chinese)
[66]	WANG J J, ZENG Z W, XIAO R Z, et al. Recent advances of chitosan nanoparticles as drug carriers[J]. Int J Nanomedicine, 2011, 6:765-774.
[67]	ETEWA S E, EL-MAATY D A A, HAMZA R S, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice[J]. J Parasit Dis, 2018, 42(1):102-113.
[68]	HAGRAS N A E, ALLAM A F, FARAG H F, et al. Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles[J]. Exp Parasitol, 2019, 204:107717.
[69]	TEIMOURI A, AZAMI S J, KESHAVARZ H, et al. Anti- Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain[J]. Int J Nanomedicine, 2018, 13:1341-1351.
[70]	GAAFAR M R, MADY R F, DIAB R G, et al. Chitosan and silver nanoparticles:promising anti- toxoplasma agents[J]. Exp Parasitol, 2014, 143:30-38.https://www.sciencedirect.com/science/article/pii/S0014489414001192.
[71]	刘涛, 张文君, 张国锋, 等. 纳米技术在中药中的应用[J]. 药学研究, 2022, 41(3):187-194, 201.LIU T, ZHANG W J, ZHANG G F, et al. Application of nanotechnology in traditional Chinese medicine[J]. Journal of Pharmaceutical Research, 2022, 41(3):187-194, 201. (in Chinese)
[72]	郑海生, 蓝育青, 钟兴武, 等. 姜黄素纳米粒对人视网膜色素上皮细胞增殖的影响[J]. 中国组织工程研究, 2022, 26(27):4335-4339.ZHENG H S, LAN Y Q, ZHONG X W, et al. Effect of curcumin nanoparticles on proliferation of human retinal pigment epithelial cells[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(27):4335-4339. (in Chinese)
[73]	AZAMI S J, TEIMOURI A, KESHAVARZ H, et al. Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice[J]. Int J Nanomedicine, 2018, 13:7363-7374.
[74]	LU J M, JIN G N, LU Y N, et al. Resveratrol modulates Toxoplasma gondii infection induced liver injury by intervening in the HMGB1/TLR4/NF-κB signaling pathway[J]. Eur J Pharmacol, 2021, 910:174497.
[75]	RAHIMI H M, KHOSRAVI M, HESARI Z, et al. Anti- Toxoplasma activity and chemical compositions of aquatic extract of Mentha pulegium L. and Rubus idaeus L.:An in vitro study[J]. Food Sci Nutr, 2020, 8(7):3656-3664.
[76]	PATRA J K, DAS G, FRACETO L F, et al. Nano based drug delivery systems:recent developments and future prospects[J]. J Nanobiotechnol, 2018, 16(1):71.